ImmPACT Bio Announces Completion of Merger with Kalthera to Progress Next-Generation CAR T Therapies for the Treatment of Cancer

ImmPACT Bio USA, Inc., a company developing novel cell therapies for treating cancer, today announced its merger with Kalthera, Inc., a biotechnology company. ImmPACT Bio is backed by OrbiMed, Novartis Venture Fund, Johnson & Johnson Innovation – JJDC, Inc., Takeda Ventures, Inc., RM Global Partners (RMGP) BioPharma Investment Fund, Bukwang Pharmaceutical, Hayan Health Networks, Inc., and JVC Investment Partners.
（以上内容由医药魔方AI生成）